Finance

Lists
Why is KLRS down 4.96%?
Dive Deeper
KLRS:NASDAQ
Kalaris Therapeutics Inc
$2.30
-4.96%
(-0.12) 1D
$2.30
+0.18% (+0.0042)
Pre-market
Closed: Nov 9, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
$2.49
High
$2.50
Low
$2.28
Mkt. cap
54.75M
Avg. vol.
82.36K
Volume
0.00
52-wk high
$11.88
52-wk low
$1.78
EPS
-$2.09
Beta
0.47
Shares outstanding
23.80M
No. of employees
20
Open
$2.49
High
$2.50
Low
$2.28
Mkt. cap
54.75M
Avg. vol.
82.36K
Volume
0.00
52-wk high
$11.88
52-wk low
$1.78
EPS
-$2.09
Beta
0.47
Shares outstanding
23.80M
No. of employees
20
News stories
From web sources and news partners
About Kalaris Therapeutics Inc
CEO-
Employees20
Founded2019
HeadquartersBerkeley Heights, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websitekalaristx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current $2.30
$17.00 (+639.13%)
Average
$15.50 (+573.91%)
Lowest
$14.00 (+508.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
$14.00
+508.7%
08/12/2026
Yun Zhong
Wedbush
Buy
Reiterated
$17.00
+639.1%
08/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/11/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$25.00
+987%
05/13/2026
Biren Amin
Piper Sandler
Hold
Maintained
$7.00
+204.3%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
$19.00
+726.1%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.13M
7.16M
7.57M
9.02M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.62M
3.64M
4.26M
3.37M
Operating expense
12.74M
10.80M
11.83M
12.39M
Total operating expenses
12.74M
10.80M
11.83M
12.39M
Operating income
-12.74M
-10.80M
-11.83M
-12.39M
Other non operating income
847.00K
803.00K
977.00K
871.00K
EBT including unusual items
-11.89M
-10.00M
-10.86M
-11.52M
EBT excluding unusual items
-11.89M
-10.00M
-10.86M
-11.52M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.89M
-10.00M
-10.86M
-11.52M
Net profit margin
-
-
-
-
Earnings per share
-0.64
-0.44
-0.46
-0.48
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.74M
-10.79M
-11.82M
-12.38M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps